Logo image of SQZ

SQZ BIOTECHNOLOGIES CO (SQZ) Stock Fundamental Analysis

NYSE:SQZ - New York Stock Exchange, Inc. - US78472W1045 - Common Stock - Currency: USD

0.435  +0.16 (+61.11%)

After market: 0.4384 +0 (+0.78%)

Fundamental Rating

3

SQZ gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. SQZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SQZ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SQZ had negative earnings in the past year.
SQZ had a negative operating cash flow in the past year.
In the past 5 years SQZ always reported negative net income.
SQZ had negative operating cash flow in 4 of the past 5 years.
SQZ Yearly Net Income VS EBIT VS OCF VS FCFSQZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

SQZ has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SQZ Yearly ROA, ROE, ROICSQZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SQZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SQZ Yearly Profit, Operating, Gross MarginsSQZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SQZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
SQZ has more shares outstanding than it did 1 year ago.
SQZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SQZ Yearly Shares OutstandingSQZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
SQZ Yearly Total Debt VS Total AssetsSQZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

SQZ has an Altman-Z score of -7.89. This is a bad value and indicates that SQZ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.89, SQZ is not doing good in the industry: 73.06% of the companies in the same industry are doing better.
SQZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.89
ROIC/WACCN/A
WACC8.56%
SQZ Yearly LT Debt VS Equity VS FCFSQZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.50 indicates that SQZ has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.50, SQZ is doing worse than 63.71% of the companies in the same industry.
A Quick Ratio of 3.50 indicates that SQZ has no problem at all paying its short term obligations.
With a Quick ratio value of 3.50, SQZ is not doing good in the industry: 62.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.5
SQZ Yearly Current Assets VS Current LiabilitesSQZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

SQZ shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.89%.
SQZ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.08%.
SQZ shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.22% yearly.
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-24.08%
Revenue growth 3Y2.22%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 60.76% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 155.08% on average over the next years. This is a very strong growth
EPS Next Y19.72%
EPS Next 2Y32.19%
EPS Next 3Y20.67%
EPS Next 5Y60.76%
Revenue Next Year65.7%
Revenue Next 2Y134.76%
Revenue Next 3Y108.16%
Revenue Next 5Y155.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SQZ Yearly Revenue VS EstimatesSQZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
SQZ Yearly EPS VS EstimatesSQZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40 50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SQZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SQZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SQZ Price Earnings VS Forward Price EarningsSQZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SQZ Per share dataSQZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SQZ's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.19%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SQZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SQZ BIOTECHNOLOGIES CO

NYSE:SQZ (7/3/2023, 8:01:56 PM)

After market: 0.4384 +0 (+0.78%)

0.435

+0.16 (+61.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2023-05-10/amc
Earnings (Next)08-02 2023-08-02/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners10.69%
Ins Owner Change0%
Market Cap12.83M
Analysts76.67
Price Target19.38 (4355.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.49%
Min EPS beat(2)-10.01%
Max EPS beat(2)62.99%
EPS beat(4)3
Avg EPS beat(4)15.45%
Min EPS beat(4)-10.01%
Max EPS beat(4)62.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.37%
Min Revenue beat(2)-100%
Max Revenue beat(2)130.74%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-100%
Max Revenue beat(4)130.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.45%
EPS NY rev (1m)0%
EPS NY rev (3m)6.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-46.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)33.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-2.96
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0.63
BVpS1.36
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 3.5
Altman-Z -7.89
F-Score2
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)57.84%
Cap/Depr(5y)90.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y19.72%
EPS Next 2Y32.19%
EPS Next 3Y20.67%
EPS Next 5Y60.76%
Revenue 1Y (TTM)-24.08%
Revenue growth 3Y2.22%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year65.7%
Revenue Next 2Y134.76%
Revenue Next 3Y108.16%
Revenue Next 5Y155.08%
EBIT growth 1Y1.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year229.46%
EBIT Next 3Y53.65%
EBIT Next 5YN/A
FCF growth 1Y-1.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.72%
OCF growth 3YN/A
OCF growth 5YN/A